Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Apatinib Compared with Conventional Transarterial Chemoembolization Plus Apatinib in the Treatment of Unresectable Hepatocellular Carcinoma

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. doi:10.3322/caac.2166033538338
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.01929628281
   PubMed Web of Science ®Google Scholar
• Acunaş B, Rozanes I. Hepatocellular carcinoma: treatment with transcatheter arterial chemoembolization. Eur J Radiol. 1999;32(1):86–89. doi:10.1016/s0720-048x(99)00117-510580325
   PubMed Web of Science ®Google Scholar
• Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007;46(3):474–481. doi:10.1016/j.jhep.2006.10.02017239480
   PubMed Web of Science ®Google Scholar
• Song MJ, Chun HJ, Song DS, et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol. 2012;57(6):1244–1250. doi:10.1016/j.jhep.2012.07.01722824821
   PubMed Web of Science ®Google Scholar
• Golfieri R, Giampalma E, Renzulli M, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014;111(2):255–264. doi:10.1038/bjc.2014.19924937669
   PubMed Web of Science ®Google Scholar
• Xie ZB, Wang XB, Peng YC, et al. Systematic review comparing the safety and efficacy of conventional and drug-eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma. Hepatol Res. 2015;45(2):190–200. doi:10.1111/hepr.1245025388603
   PubMed Web of Science ®Google Scholar
• Farid K, Elalfy H, Abo El-Khair SM, et al. Prognostic value of vascular endothelial growth factor in both conventional and drug eluting beads transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma in HCV patients. Expert Rev Gastroenterol Hepatol. 2020;14(12):1203–1214. doi:10.1080/17474124.2020.182321532933325
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390. doi:10.1056/NEJMoa070885718650514
   PubMed Web of Science ®Google Scholar
• Connock M, Round J, Bayliss S, Tubeuf S, Greenheld W, Moore D. Sorafenib for the treatment of advanced hepatocellular carcinoma. Health Technol Assess. 2010;14(Suppl 1):17–21. doi:10.3310/hta14suppl1-0320507799
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. doi:10.1016/s1470-2045(08)70285-719095497
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24(26):4293–4300. doi:10.1200/jco.2005.01.344116908937
   PubMed Web of Science ®Google Scholar
• Kou P, Zhang Y, Shao W, et al. Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review. Oncotarget. 2017;8(12):20510–20515. doi:10.18632/oncotarget.1472428103584
   PubMedGoogle Scholar
• Scott LJ. Apatinib: a review in advanced gastric cancer and other advanced cancers. Drugs. 2018;78(7):747–758. doi:10.1007/s40265-018-0903-929663291
   PubMed Web of Science ®Google Scholar
• Wang Y, Gou Q, Xu R, Chen X, Zhou Z. Efficacy and safety of sorafenib versus apatinib in the treatment of intermediate and advanced hepatocellular carcinoma: a comparative retrospective study. Onco Targets Ther. 2018;11:3407–3413. doi:10.2147/ott.S16102329928132
   PubMed Web of Science ®Google Scholar
• Lu W, Jin XL, Yang C, et al. Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: a single-center randomized controlled trial. Cancer Biol Ther. 2017;18(6):433–438. doi:10.1080/15384047.2017.132358928548587
   PubMed Web of Science ®Google Scholar
• Chen S, Yu W, Zhang K, Liu W. Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma. BMC Cancer. 2018;18(1):1131. doi:10.1186/s12885-018-5081-330453925
   PubMed Web of Science ®Google Scholar
• Zhu Y, Feng B, Mei L, Sun R, Guo C, Zhu J. Clinical efficacy of TACE combined with Apatinib in the treatment of advanced hepatocellular carcinoma. J BUON. 2019;24(2):608–614.31128013
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–216. doi:10.1093/jnci/92.3.20510655437
   PubMed Web of Science ®Google Scholar
• Gorodetski B, Chapiro J, Schernthaner R, et al. Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization. Eur Radiol. 2017;27(2):526–535. doi:10.1007/s00330-016-4445-927277261
   PubMed Web of Science ®Google Scholar
• Kan X, Liang B, Zhou G, et al. Transarterial chemoembolization combined with apatinib for advanced hepatocellular carcinoma: a propensity score matching analysis. Front Oncol. 2020;10:970. doi:10.3389/fonc.2020.0097032733791
   PubMed Web of Science ®Google Scholar
• Yang Z, Chen G, Cui Y, et al. The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study. Cancer Biol Ther. 2019;20(3):321–327. doi:10.1080/15384047.2018.152909930332553
   PubMed Web of Science ®Google Scholar
• Fan W, Yuan G, Fan H, et al. Apatinib combined with transarterial chemoembolization in patients with hepatocellular carcinoma and portal vein tumor thrombus: a multicenter retrospective study. Clin Ther. 2019;41(8):1463–1476. doi:10.1016/j.clinthera.2019.04.03631303279
   PubMed Web of Science ®Google Scholar
• Shen L, Chen S, Qiu Z, et al. Transarterial chemoembolization combined with apatinib versus transarterial chemoembolization alone for hepatocellular carcinoma with macroscopic vascular invasion: a propensity score matching analysis. J Cancer Res Ther. 2020;16(5):1063–1068. doi:10.4103/jcrt.JCRT_801_1933004748
   PubMed Web of Science ®Google Scholar
• Liu J, Xu J, Zhang W, et al. Safety and efficacy of drug-eluting bead transarterial chemoembolization combined with apatinib in patients with advanced hepatocellular carcinoma. Acad Radiol. 2020;27(5):704–709. doi:10.1016/j.acra.2019.07.00331375353
   PubMed Web of Science ®Google Scholar
• Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 1998;28(3):751–755. doi:10.1002/hep.5102803229731568
   PubMed Web of Science ®Google Scholar
• Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329–338. doi:10.1055/s-2007-100712210518312
   PubMed Web of Science ®Google Scholar
• Wu S, Zeng N, Sun F, et al. Hepatocellular carcinoma prediction models in chronic hepatitis B: a systematic review of 14 models and external validation. Clin Gastroenterol Hepatol. 2021. doi:10.1016/j.cgh.2021.02.040
   Web of Science ®Google Scholar
• Dawood RM, Salum GM, El-Meguid MA, et al. Development of a gene signature for predicting cirrhosis risk score of chronic liver disease associated with HCV infection in Egyptians. Microb Pathog. 2021;153:104805. doi:10.1016/j.micpath.2021.10480533609649
   PubMed Web of Science ®Google Scholar